Antibody–drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. [1] . Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. As of 2019, some 56 pharmaceutical companies were developing ADCs. [2]

2022年4月24日 · 抗体-药物偶联物 (ADC)由linker、payload、单克隆抗体 (mAb) 组成。 它结合了高特异性靶向能力和强效杀伤作用的优势，实现了对癌细胞的精准高效杀灭，已成为抗癌药物研发的热点之一。 自第一个 ADC 药物Mylotarg ®（gemtuzumab ozogamicin）于2000年获得FDA批准以来，截至2021 年 12 月全球共有 14 款 ADC 药物获批用于血液系统恶性肿瘤和实体瘤，此外，目前还有100多个ADC候选者处于临床试验的不同阶段。

2024年1月8日 · Antibody–drug conjugates (ADCs) are a promising cancer treatment modality that enables the selective delivery of highly cytotoxic payloads to tumours.

Antibody–drug conjugates (ADCs) are an innovative family of agents assembled through linking cytotoxic drugs (payloads) covalently to monoclonal antibodies (mAbs) to be delivered to tumor tissue that express their particular antigen, with the theoretical advantage of an augmented therapeutic ratio.

2022年3月22日 · In 2000, the U.S. Food and Drug Administration (FDA) firstly approved ADC drug, Mylotarg® (gemtuzumab ozogamicin), for adults with acute myeloid leukemia (AML), which marked the beginning of...

Antibody-drug conjugates (ADC) are one of the fastest growing anticancer drugs. This approach comprises a mAb conjugated to the cytotoxic payload via a chemical linker that directed toward a target antigen expressed on the cancer cell surface, …

2024年1月5日 · Antibody-drug conjugates (ADCs) are a class of innovative biopharmaceutical drugs, which, via their antibody (mAb) component, deliver and release their potent warhead (a.k.a. payload) at the disease site, thereby simultaneously improving the efficacy of delivered therapy and reducing its off-target toxicity.

2025年3月10日 · ADC药物，即抗体偶联药物（Antibody–drug conjugates），被称为“生物导弹”，它像精准导航系统一样，将化疗药物直接送到肿瘤细胞内部，减少对正常细胞的伤害。

2023年5月25日 · The fundamental components of an antibody-drug conjugate (ADC) include an antibody, a linker, and a payload, and the choice and construction determine the clinical characteristics of the ADC. Recent drug development has focused on altering linker chemistry and tapping into novel cytotoxic payloads to generate high-potency ADCs that have ...

2023年9月18日 · Antibody-Drug Conjugates (ADCs) represent an innovative class of potent anti-cancer compounds that are widely used in the treatment of hematologic malignancies and solid tumors. Unlike conventional chemotherapeutic drug-based therapies, that are mainly associated with modest specificity and therapeu …